Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dana-Farber Cancer Institute
OBJECTIVES:
Primary
To determine rate of local-regional control at 2 years
Secondary
To determine Progression Free Survival at 2 and 5 years
To determine Overall Survival at 2 and 5 years
To assess acute toxicity and long term toxicity of reduced radiation dose at 2 and 5 years
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed squamous cell carcinoma of the oropharynx or unknown primary that is HPV 16 positive as determined by ISH and p16 positive as determined by IHC.
Stage 3 or 4 disease without evidence of distant metastases
At least one evaluable or uni- or bi-dimensionally measurable lesion by RECIST 1.1 criteria
18 years of age or older
No previous surgery, radiation therapy or chemotherapy for SSCHN is allowed at time of study entry
ECOG Performance Status of 0 or 1
No active alcohol addiction
Adequate bone marrow, hepatic and renal function as defined in the protocol
Women of child-bearing potential must have a negative pregnancy test within 7 days of starting treatment
You may not be if
Pregnant or breast feeding women or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least 3 months after
Previous or current malignancies at other sites
Symptomatic peripheral neuropathy of grade 2 or greater
Symptomatic altered hearing greater than grade 2
Other serious illnesses or medical conditions
Patients that have experienced an involuntary weight loss of more than 25% of their body weight in the 2 months preceding study entry
Concurrent treatment with any other anticancer therapy
Participation in an investigational trial within 30 days of study entry
